H.C. Wainwright Starts Coverage on Inhibikase Therapeutics With Buy Rating

H.C. Wainwright begins coverage of Inhibikase Therapeutics with a Buy rating and $8 target, citing strong prospects for its Phase 3 PAH drug IKT-001.